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Background: Cardiomyopathy and distal symmetrical polyneuropathy (DSPN), including sensory and autonomic
dysfunction, often co-occur in diabetic mellitus (DM) patients. However, the temporal relationship and progression
between these two complications has not been investigated. Using a streptozotocin DM animal model that develops in-
sensate neuropathy, our aim was to examine in parallel the development of DSPN and DM-associated changes in
cardiac structure and function as well as potential mechanisms, such as autonomic dysfunction, evaluated by changes in
urinary and myocardial norepinephrine content and myocardial neuronal markers.
Methods: Sensory neuropathy was measured by behavioral tests using Von Frey filaments and Hargreaves methods.
Echocardiography was used to evaluate myocardial structure and function. Autonomic function was evaluated by
measuring urinary and myocardial norepinephrine (NE) levels by enzyme-linked immunosorbent assay and high-
performance liquid chromatography/mass spectrometry. Quantitative immunohistochemistry was used to measure the
myocardial neuronal markers, calcitonin gene-related peptide (CGRP) and general neuronal protein gene product 9.5
(PGP 9.5).
Results: The DM group developed tactile and thermal insensate neuropathy 4–5 weeks after DM onset. Cardiovascular
changes were found between 4 and 12 weeks after DM onset and included bradycardia, diastolic and systolic
dysfunction and cardiac dilation. There was a 2.5-fold reduction in myocardial NE levels and a 5-fold increase in urinary
NE levels in the DM group. Finally, there was a 2.3-fold increase in myocardial CGRP levels in the DM group and no
change in PGP9.5 levels.
Conclusions: Cardiovascular structural and functional changes developed early in the course of DM and in
combination with insensate neuropathy. In parallel, signs of cardiac autonomic dysfunction were also found and
included decreased myocardial NE levels and altered CGRP levels. These results may indicate the need for early
cardiovascular evaluation in DM patients with insensate neuropathy.
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Diabetes mellitus (DM) is associated with many disabling
complications, including nephropathy, retinopathy, poly-
neuropathy, and cardiomyopathy. Among these com-
plications, polyneuropathy such as distal symmetrical
polyneuropathy (DSPN) and other peripheral neuropathies
are the most common long-term complication of DM* Correspondence: piano@uic.edu
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article, unless otherwise stated.affecting >50% of patients. Cardiovascular disease, however,
is the leading cause of death. Adults with DM have cardio-
vascular disease death rates that are 2–3 times higher than
adults without DM [1]. Cardiovascular complications can
include coronary artery disease and diabetic cardiomyop-
athy. Diabetic cardiomyopathy occurs independently of
underlying coronary artery disease or hypertension and
is characterized by a dilated ventricular phenotype, as
well as diastolic and systolic dysfunction [2].
Data from population-based studies support that DM
complications often cluster and coexist. For example,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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opathy and nephropathy occurred more often in type 2
DM patients with DSPN, a sensory neuropathy [3].
There is also evidence that co-occurrence of DSPN and
cardiac autonomic neuropathy is associated with changes
in ventricular structure and function [4,5]. Others have
found that cardiac autonomic neuropathy is an inde-
pendent predictor of cardiovascular disease mortality
[6]. Despite the frequent co-occurrence of DSPN and
myocardial dysfunction, the temporal relationship of
the onset and progression of these complications has
not been fully investigated. Insensate neuropathy is a
pathogenic hallmark of DSPN and contributes to the
high prevalence of unawareness or the asymptomatic
nature of DSPN. Diabetes duration and blood glucose
control/variability correlate with the development of
DSPN; however, these mechanisms do not fully account
for the onset of DM complications, such as DSPN, sug-
gesting the involvement of other factors, such as loss of
insulin signaling [7]. Diabetic cardiomyopathy also involves
impairment of myocardial autonomic neurons and direct
neuronal damage to afferent and efferent fibers, leading
to cardiac autonomic dysregulation and silent myocardial
infarction [8]. Several studies have evaluated myocardial
norepinephrine (NE) levels and myocardial sympathetic
and parasympathetic density separately, but no study
has measured these variables together in the same animal
model.
Therefore, using a non-insulin-dependent streptozo-
tocin (STZ) DM animal model that develops insensate
neuropathy, the purpose of this investigation was to
examine in parallel the development of DSPN and DM-
associated changes in cardiac structure and function, as
well as potential mechanisms, such as autonomic dysfunc-
tion, evaluated by changes in urinary and myocardial NE
content and myocardial neuronal markers. Myocardial
neuronal markers evaluated included, calcitonin gene-
related peptide (CGRP) a marker for sensory fibers, and
PGP9.5, as general neuronal marker. In our STZ-DM ani-
mal model, we found early development of cardiovascular
functional and structural changes in the presence of in-
sensate neuropathy with signs of autonomic deficits.
Methods
Animals and induction of diabetes mellitus
A total of 38 adult male Fischer 344 rats (300 g, 16
week-old, Charles River, MA) were studied. Diabetes
mellitus was induced with a single tail vein injection of
STZ (Sigma-Aldrich Chemicals, St. Louis, MO, 35 mg/kg;
Week 0, baseline). The control (CON) group received an
equal volume of vehicle (0.1 mol/l citrate buffer, pH 4.5).
Both groups received standard rat chow and water ad
libitum. Animals were weighed at weekly intervals, and
blood glucose levels were measured using the Freestyleglucose monitoring system (Therasense®, Alameda, CA).
One week following STZ injection, all animals developed
hyperglycemia with glucose values exceeding 300 mg/dL
(STZ-DM group). Diabetic animals were monitored for
polydipsia, polyuria, and weight loss. A onetime high dose
of STZ in adult animals kills a proportion of pancreatic
beta cells rendering the animal hypoinsulinemic and
hyperglycemic but with sufficient residual insulin for short-
term survival. All procedures were performed in accord-
ance with the Guide for the Care and Use of Laboratory
Animals published by the U.S. National Institutes of Health
(National Institutes of Health, Publication No. 85–23, re-
vised 1996) and approved by the University of Illinois at
Chicago Institutional Animal Care and Use Committee.
Behavioral testing
Development of sensory neuropathy was measured by two
methods in CON (n = 12) and STZ-DM animals (n = 13).
Animals were tested for behavioral responses to noxious
thermal stimuli using the Hargreaves method [9] and to
non-noxious sensory stimuli using flexible Von Frey fila-
ments [10]. Both tests were performed before injections
and weekly thereafter through Week 8. Animals were
placed in individual cages, and behavioral accommodation
was allowed until there was cessation of cage exploration
and major grooming activities. Stimuli were presented to
mid-plantar sections of both hind paws. Briefly, for Von
Frey methods a floorless fiberglass box (18 × 8 ×8 cm)
was placed on top of an elevated mesh floor for paw
access. Von Frey threshold was calculated using the
up-and-down method of Dixon [11]. For the Hargreaves
method, rats were placed under an inverted clear fiber-
glass box (18 × 8 × 8 cm) on top of an elevated glass
floor and allowed to acclimate. The radiant heat source
(Ugo Basile Biological Research Apparatus Model 737150,
Comerio, Italy) was positioned under the glass floor
directly beneath the hind paw, and the thermal latency
was measured in seconds.
Echocardiography
All echocardiograms were performed as previously de-
scribed by our laboratory and according to the American
Society of Echocardiography guidelines [12]. Echocardio-
grams were performed in CON (n = 6) and STZ-DM ani-
mals (n = 7) at 4, 8, and 12 weeks by the same experienced
sonographer using the Sequoia C256 Echocardiography
System (Acuson Corporation, Mountain View, CA) and a
15.0 MHz transducer. Before the procedure, animals were
anesthetized with an initial dose of methoxyflurane, and
sedation was maintained thereafter via intubation with 1%
isoflurane, using a Harvard small-animal ventilator (respira-
tory rate 80 breaths per minute, respiratory volume 2.5 ml).
Body temperature was maintained at 37°C using a warming
plate perfused with a water circulating bath. The transducer
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dimensional echocardiography images were obtained in
the papillary muscle level.
The measurements listed were obtained after a well-
defined, continuous interface of the anterior and posterior
walls was visualized. All parameters were measured with
electronic calipers, and mean calculations were obtained
from three or more consecutive cardiac cycles. After
good visualization, left ventricular end-diastolic dimension
(LVDD), left ventricular end-systolic dimension (LVSD)
and interventricular septal thickness in diastole (IVSD)
and in systole (IVSS) were measured by the leading edge
method [13]. The former two parameters reflect intraven-
tricular volume and therefore dilation of the left ventricle
and IVSD and IVSS, reflect the wall thickness of the septal
wall during diastole and systole. In all animals, three to
four beats were recorded using the same transducer
position. Fractional shortening (FS) and relative wall
thickness (RWT) were calculated as previously described
[12]. LV mass was calculated using the following equation:
LV mass = 1.04 × [(LVDD + posterior wall thickness +
IVSD)3 - LVDD3]. Using pulse-wave Doppler echocardiog-
raphy, we also measured signals from the left ventricular
inflow and outflow track and obtained indices of diastolic
function. These included isovolumic relaxation time (IVRT),
which reflects the time between the closure of the aortic
valve and opening of the mitral value, deceleration time
(DecT), and E/A ratio, in which the E wave represents
early rapid filling of the ventricle and the A wave repre-
sents late filling of the ventricle. Mean values were used
for statistical analysis.
Urine and myocardial norepinephrine levels
At 8 weeks, in a subgroup of CON (n = 5) and STZ-DM
(n = 6), we measured urinary and myocardial NE levels.
Twenty-four hour urine samples were collected for the
measurement of NE and creatinine [12]. The total 24 h
volume was measured, and 1-ml aliquots (containing
6 mol/l hydrochloride) were stored at −20°C until assay.
Norepinephrine was measured by enzyme-linked immu-
nosorbent assay (Rocky Mountain Diagnostics, Colorado
Springs, CO). All samples were run in duplicate and nor-
malized to urinary creatinine to correct for urine volume
[14]. Norepinephrine levels were expressed as mmol/l 24 h
NE/creatinine.
Following the 24 hour urine collection, animals were
anesthetized with CO2 and then euthanized by cervical
dislocation. Hearts were excised, rinsed in phosphate
buffered solution, weighed and snap frozen in liquid
nitrogen and stored at −70°C. Catecholamine levels in
biological samples can change over time due to auto-
oxidation, exposure to light, air oxidation and/or exposure
to high pH and temperature [15]. Therefore as noted
below certain procedures/techniques were used whenhandling, storing and preparing samples to avoid deg-
radation of NE. Frozen myocardial tissue samples were
pulverized in liquid nitrogen and homogenized in glass
homogenizers to minimize oxidation from metal homoge-
nizers on ice in buffer (2 ml/g tissue) containing 0.1 N
perchloric acid and 0.02 mmol/l EDTA. To control for
oxidation of NE two homogenization buffers were tested,
with and without sodium metabisulfite (see Additional
file 1). Sodium metabisulfite, a commonly used antioxidant,
quenched the NE signal and therefore was not used for the
homogenization of samples. Homogenates were centrifuged
(15,000 g, 20 min, 4°C), and the resulting supernatants
were used for NE extraction and aliquots stored at −80°C.
As previously described, samples were analyzed using a
high-performance liquid chromatograph (Agilent 1200
series high performance liquid chromatography system,
Santa Clara, CA) and Agilent Zorbax Rx-C8 (150 × 2.1 mm
I.D., 5 μm) column, along with a pre-column filter (used in
the isocratic, reverse-phase, ion-paring mode) coupled
with tandem mass spectrometry detection [16]. The mobile
phase consisted of water–methanol-heptafluorobutyric acid
(85/15/.13, V/V/V), with a flow rate of 0.2 ml min-1. The
entire chromatographic effluent (10 μl) was passed through
the mass spectrometer interface for subsequent detection.
Under these conditions, NE retention time was about
4.4 min resulting in a total time (injection-to-injection)
of 6 min. Deuterium-NE (d-NE) (Fisher #NC9750934,
Pittsburgh, PA) was used as an internal standard. NE/d-NE
area ratios were determined for the SRM chromatographic
peaks using Agilent’s MassHunter software. Calibration
curves were generated by plotting peak area ratios (NE/
d-NE) obtained from working standard versus NE con-
centrations and fitting these data to a weighted (1/x)
linear regression curve.
Evaluation of neuronal markers
The myocardial neuronal markers calcitonin gene-related
peptide (CGRP) and PGP9.5 were also evaluated at 8
weeks in a separate subgroup of CON (n = 3) and STZ-
DM (n = 4) animals. After euthanasia as described above,
hearts were removed and pulverized with a ceramic grinder
under liquid nitrogen and homogenized on ice in cold
buffer (10 ml/g tissue) containing: 50 mmol/l 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid buffer (pH 7.4),
5 mmol/l ethylenediaminetetraacetic acid, 150 mmol/l
NaCl, 1% Triton X-100, 1X phosphatase inhibitor cocktail
set II (Calbiochem #524625, Billerica, MA), 1X protease
inhibitor cocktail (Sigma #P8340, St. Louis, MO), and
50 nmol/l okadaic acid. Homogenates were centrifuged
at 14,000 rpm for 15 min at 4°C, and supernatants were
used for blots. A small aliquot was reserved for protein
quantification by bicinchoninic acid (Pierce #23225, Thermo
Scientific, Hanover Park, IL). Supernatants with sample
buffer were loaded onto a 4-12% Bis/Tris gradient gel
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ducing conditions. Samples were incubated overnight
at 4°C with primary antibodies against calcitonin gene-
related peptide (CGRP, Millipore AB15360, Billerica, MA,
1:5,000), protein gene product 9.5 (PGP 9.5, Millipore
AB1761, Billerica, MA, 1:2,000) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, Abcam 341048,
Cambridge, MA, 1:5,000). Corresponding secondary anti-
bodies conjugated with horseradish peroxidase enzyme
goat anti-rabbit (Jackson ImmunoResearch, West Grove,
PA, #111-035-045) and goat anti-mouse (Jackson Immu-
noResearch, West Grove, PA, #115-035-044) were added
to samples, and membranes were washed of unbound
secondary antibodies, followed by incubation with peroxid-
ase substrate for enhanced chemiluminescence and detec-
tion by film processor. Using Image J software (National
Institutes of Health), optical densitometry was calculated
and normalized to GAPDH.
Statistical analyses
All data are expressed as mean ± SEM. Normally distrib-
uted data (body weight, glucose measurements, Hargreaves,
and echocardiograms) were compared using two-way
repeated measures analysis of variance (RM-ANOVA),
followed by the Holm-Sidak method for multiple compari-
son. Student's t test was used for two-group parametric
comparisons (urinary and myocardial NE, Immunoblots).
The Mann–Whitney test was used to compare non-para-
metric data at each interval (von Frey filaments). A p value
less than 0.05 was considered significant. Statistical ana-




Glucose levels measured at 4, 8, and 12 weeks were sig-
nificantly greater in the STZ-DM animals compared to
CON rats (Table 1). After DM induction and at all time
points, body weight (BW) in STZ-DM animals was sig-
nificantly lower than in CON animals (Table 1). STZ-
DM animals exhibited polydipsia, polyuria, diarrhea, andTable 1 Body weight and glucose in CON and STZ-treated
F344 rats
Groups 4 weeks 8 weeks 12 weeks
Body weight (g)
CON (n = 6) 340 ± 5 378 ± 7 396 ± 10
STZ-DM (n = 7) 255 ± 9a 256 ± 13a 239 ± 13a
Glucose (mg/dL)
CON (n = 6) 87 ± 7 68 ± 4 76 ± 4
STZ-DM (n = 7) 370 ± 22a 373 ± 28a 398 ± 30a
Data are expressed as mean ± SEM. CON: control; STZ-DM: streptozotocin-
induced diabetes mellitus. Two-way RM ANOVA, Holm-Sidak method.
ap < 0.001 STZ-DM vs CON.weight loss. No STZ-DM animals required insulin ad-
ministration and no animals were euthanized for animal
welfare issues.
Evaluation of DSPN
Within the CON group, no changes in thermal latency or
Von Frey threshold values were found over time (Figure 1,
panel a and b, respectively). Within the STZ-DM group,
compared to baseline (Week 0), significant increases in
thermal latency were found at 5 through 8 weeks (Figure 1,
panel a). Compared to the CON group, significant increases
in thermal latency were found in the STZ-DM group at 4–
8 weeks (Figure 1, panel a). Within the STZ-DM group,
compared to baseline, no differences were found in Von
Frey threshold over time. Compared to the CON group,
significant increases were found in Von Frey threshold in
the STZ-DM group at 5 and 8 weeks (Figure 1, panel b).
Echocardiography
Within the CON group, no changes in echocardiography
parameters were found over time (Table 2). At 8 and 12
weeks, heart rate was significantly lower in the STZ-DM
group compared to the CON group (Table 2). At all time
points, LVDD/BW and LVSD/BW were significantly
greater in the STZ-DM group compared to the CON
group (Table 2). Except for a significant increase in
IVSS/BW in the STZ-DM group compared to the CON
group at 4 weeks (p < 0.05), no differences in IVSD/BW
or IVSS/BW were found between groups at other time
points. At 4 weeks, left ventricular mass/BW was signifi-
cantly lower in the STZ-DM group compared to the CON;
while at 8 weeks, in the STZ-DM group, left ventricular
mass/BW was significantly greater than that of the CON
group, and no differences were found between groups at
12 weeks (Table 2). At all time points, the STZ-DM group
compared to the CON group showed significantly lower
RWT/BW; significantly lower fractional shortening (%);
significantly greater IVRT; and significantly lower E/A
ratio. No changes were found at any time point in de-
celeration time of the myocardium between groups.
Over time in the STZ-DM group, there were progres-
sive changes in heart rate, cardiac structure, and function.
Compared to baseline, heart rate was significantly lower at
12 weeks (Figure 2, panel a), while LVDD/BW and LVSD/
BW were significantly increased at 12 weeks (Figure 2,
panel b). Similarly, compared to baseline, RWT/BW and
fractional shortening (%) were significantly reduced at 12
weeks (Figure 2, panel c and d, respectively).
Urine and myocardial tissue norepinephrine
Urinary NE concentrations were greater in STZ-DM
animals compared to CON animals (Figure 3, panel a).
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Figure 1 Behavioral responses of rats to mechanical and thermal stimulation of hind paws. Data are mean ± SEM. CON: control (black
squares, n = 13); STZ-DM: streptozotocin-induced diabetes mellitus (white circles, n = 12). (a) Thermal latencies measured by Hargreaves method
in CON and STZ-DM groups. Two-way RM ANOVA CON vs. STZ-DM: *p < 0.05; **p < 0.001; STZ-DM 5–8 weeks vs. Week 0 + p < 0.05. (b) Von Frey
threshold was measured using up-and-down method in CON and STZ-DM groups. Mann–Whitney test CON vs STZ-DM. †p < 0.05.
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(Figure 3, panel b).
Neuronal markers
No differences were found in PGP 9.5 levels between
groups (Figure 4). In contrast, CGRP levels were greater in
the STZ-DM group compared to the CON group (Figure 4).
GAPDH expression was similar between groups.
Discussion
To the best of our knowledge, using a non-insulin-
dependent animal model of DM this is the first longitudinal
study that addresses the time course and co-occurrenceDSPN and DM-induced cardiac structure and function. As
early as 4 weeks after the onset of DM, we found evidence
of ventricular remodeling and systolic dysfunction, exem-
plified by decreases in fractional shortening, and DSPN,
exemplified as reduced thermal sensation, indicating the
development of insensate neuropathy. In addition, both of
the latter findings occurred concomitantly with reduced
myocardial NE content and altered myocardial CGRP
levels, suggesting myocardial neuronal remodeling.
Development of insensate neuropathy
In DM animal models, manifestations of sensory neur-
opathy are commonly evaluated by quantitative sensory
Table 2 Echocardiography parameters in CON and STZ-DM rats
4 weeks 8 weeks 12 weeks
Groups CON STZ-DM CON STZ-DM CON STZ-DM
(n = 6) (n = 7) (n = 6) (n = 7) (n = 6) (n = 7)
HR (bpm) 330.7 ± 13.6 314.4 ± 26.4 349.7 ± 8.5 297.9 ± 8a 328.3 ± 18.7 277.7 ± 9.3a
LVDD/BW (mm/kg) 21.90 ± 0.4 30.90 ± 1.1b 19.70 ± 0.4 32.20 ± 1.5b 19.91 ± 0.63 35.25 ± 1.9b
LVSD/BW (mm/kg) 12.40 ± 0.5 19.50 ± 1.3b 11.20 ± 0.3 21.20 ± 1.3b 12.21 ± 0.39 25.64 ± 1.5b
IVSD/BW (mm/kg) 2.68 ± 0.13 3.08 ± 0.21 2.63 ± 0.14 2.99 ± 0.15 2.24 ± 0.11 2.50 ± 0.21
IVSS/BW (mm/kg) 5.35 ± 0.32 5.98 ± 0.47a 5.19 ± 0.28 5.55 ± 0.34 4.24 ± 0.25 4.47 ± 0.32
LVmass/BW (g/kg) 1.21 ± 0.03 0.80 ± 0.06b 1.20 ± 0.07 1.45 ± 0.08a 1.12 ± 0.06 1.25 ± 0.1
RWT/BW (mm/kg) 0.44 ± 0.02 0.37 ± 0.01a 0.43 ± 0.02 0.33 ± 0.01b 0.39 ± 0.02 0.27 ± 0.01b
FS (%) 43.7 ± 2.2 37.1 ± 2.4a 43.2 ± 1.4 32.6 ± 1.3a 38.8 ± 1.1 27.4 ± 0.7a
E/A ratio 1.98 ± 0.07 1.50 ± 0.05a 1.98 ± 0.13 1.55 ± 0.12a 1.83 ± 0.15 1.35 ± 0.02a
IVRT (msec) 26.3 ± 2 34.4 ± 3a 25.3 ± 1.7 32.9 ± 2.8a 27.7 ± 1.8 38.1 ± 2.9a
DecT (msec) 45.7 ± 0.8 41.6 ± 2.6 41.2 ± 2.9 47.9 ± 3.2 44.2 ± 2.8 43.3 ± 2.5
Data are expressed as mean ± SEM; CON: control; STZ-DM: streptozotocin-induced diabetes mellitus; HR: heart rate; BW: body weight; LVDD: left ventricular end-
diastolic dimension; LVSD: left ventricular end-systolic dimension; IVSD: interventricular septum in diastole, IVSS: interventricular septum in systole; LV: left ven-
tricle; RWT: relative wall thickness; FS: fractional shortening; E/A: E wave to A wave ratio; IVRT: isovolumic relaxation time; DecT: deceleration time. Two-way RM
ANOVA Holm-Sidak test. ap < 0.05 CON vs STZ-DM; bp < 0.001 CON vs STZ-DM.
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and mechanical stimuli. These methods are non-invasive
and allow for longitudinal evaluation of sensory symp-
tom progression. In insulin-dependent and non-insulin-
dependent DM animal models, the development of sensate















































Figure 2 Time course of changes in echo-derived parameters in STZ-D
*p < 0.05. (b) Left ventricular end-diastolic dimension (LVDD/BW) and left v
12 weeks and 8 weeks vs 12 weeks. **p < 0.001. (c) Relative wall thickness
weeks vs 12 weeks. *p < 0.05. (d) Fractional shortening % (FS). Holm-Sidak
*p < 0.001. BW: body weight.investigators reporting one or the other or both. The
onset and type of neuropathy appear to be dependent
on the animal species and strain [17].
In this study, we found that STZ-DM Fischer 344 rats
exhibited reduced sensitivity to both noxious thermal
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b)
Figure 3 Urinary and myocardial NE levels in CON (n = 5) and STZ-DM (n = 6). (a) Urinary NE excretion was measured by enzyme-linked
immunoassay. (b) Myocardial NE content was measured by high performance liquid chromatography in tandem mass spectrometry. Data are
mean ± SEM. t test CON vs STZ-DM. **p < 0.001. CON: control; STZ-DM: streptozotocin-induced diabetes mellitus; NE: norepinephrine.
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is in accordance with several studies that showed impaired
sensory perception for tactile and thermal stimuli at
4 weeks [18,19] and 8 weeks [20] post-STZ in mice. Using
male Wistar rats and as early as 2 weeks post-STZ,
Sugimoto et al. found thermal hypoalgesia in parallel
with mechanical hyperalgesia [21]. Others have shown,
in male Wistar and female Sprague–Dawley rats, thermal
hyperalgesia develops at 4 weeks post-STZ and evolves
into thermal hypoalgesia between 8 and 12 weeks [22,23].
In our study, unless pain developed in a transient way in
between measurements, there was no evidence of pain at
any time point. Discrepancies in the onset and types of
neuropathy responses among studies may be attributable
to the use of different rodent strains [24,25] with different
metabolic characteristics. Specifically, our findings along
with others suggest that the Fischer 344 strain may not
develop painful neuropathy [26]. Fisher 344 rats, compared
to other rodent strains have heightened hypothalamic-
pituitary-adrenal axis activity and elevated corticosteroid
levels which may render this strain more resistance toa)
Figure 4 Myocardial neuronal markers in CON (n = 3) and STZ-DM (n
from CON and STZ-DM groups. (b) Densitometry values for PGP 9.5 and CG
STZ-DM. *p < 0.05. Data are mean ± SEM. CON: control; STZ-DM: streptozoto
CGRP: calcitonin gene-related peptide; GAPDH: glyceraldehyde-3-phosphatinflammation and other metabolic-induced symptoms,
such as pain [27]. However, to fully address possible
pain development in a Fischer 344 DM model, future
studies should include testing with noxious mechanical
and chemogenic stimuli.
Myocardial functional and structural changes
Echocardiography represents a state-of-the-art non-inva-
sive technique for the serial evaluation of functional and
structural myocardial changes. Human and animal models
of DM cardiomyopathy are characterized by both diastolic
and systolic dysfunction. Similar to others [28,29], in the
present study, diastolic dysfunction as exemplified by a
reduction in the E/A ratio and prolonged IVRT was
found at 4 weeks. However, at 4 weeks, we also found
systolic dysfunction, exemplified by a decrease in fractional
shortening (%), which became progressively lower at
both 8 and 12 weeks. With regard to systolic dysfunction,
Radovits et al. using a STZ non-insulin dependent DM
Sprague-Dawley model, found decreases in ejection frac-





























= 4). (a) Representative PGP 9.5, CGRP, and GAPDH immunoblots
RP normalized to GAPDH in CON and STZ-DM groups. t test CON vs
cin-induced diabetes mellitus; PGP 9.5: protein gene product 9.5;
e dehydrogenase.
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the latter study these contractility parameters were only
measured at 8 weeks post STZ injection. Other studies
using a similar non-insulin DM model have evaluated
cardiac function, however at later time points, such as
2 and half months and 6 months following STZ injection
[31,32]. Since our first evaluation of cardiac function was
at 4 weeks, it is possible that diastolic and systolic dysfunc-
tion could have developed at an earlier time point. Becher
et al., using a Sprague-Dawley STZ-DM model (single
STZ [70 mg/kg] injection) and using the conductance
Millar catheter technique, found significant changes in
left ventricular relaxation that occurred at 2 weeks post
STZ injection. Impaired relaxation was exemplified by
increases in left ventricular diastolic relaxation time (msec)
and decreases in left ventricular diastolic relaxation
(mm Hg/sec), these changes were also found in conjunc-
tion with decreases in cardiac output and decreased left
ventricular contractility (mm Hg/sec), indicating reduced
systolic function [33]. Changes in cardiac structure, such
as cardiac dilation were evident at 4 weeks, exemplified
by increased left ventricular end diastolic and systolic
dimensions and decreases in relative wall thickness.
Similar to others and our findings related to function,
we found that myocardial structural changes progressed
with the duration of DM [34,35]. We chose to begin
our cardiac evaluation at 4 weeks because others [34,36]
using a rodent STZ-DM model found DM-induced car-
diac changes developed 6–12 weeks after the induction
of DM. Findings from our study, suggests that both dia-
stolic and systolic dysfunction develop earlier after the
onset of DM.
Cardiac autonomic regulation and myocardial
neuronal markers
Indices of DM cardiac autonomic neuropathy in animal
models can be studied by a variety of methods, including
analysis of myocardial NE content, cardiac sympathetic
and parasympathetic innervation density, and heart rate
variability [37]. Twenty-four hour urinary NE excretion is
a commonly used biomarker to measure autonomic dys-
function [38]. Changes in plasma and urinary NE levels
have been reported in DM animal models [39]. Similar
to others, we found increased urinary NE excretion in
STZ-DM animals [40]. Interestingly, Tidholm et al. showed
that increased NE excretion correlated with reduced
myocardial FS (%), increased LVDD and LVSD in dogs
with preclinical and clinical DM [41]. Increased urinary
NE excretion could be a result of increased NE spill-over
due to either increased sympathetic tone or loss of sympa-
thetic nerve terminal function [42].
In DM animal models, results related to myocardial
NE levels have been equivocal. Some researchers have
reported increases in myocardial NE levels as early asone month following the onset/induction of DM [43]
and decreases after 12 months [44]. In the present study,
a significant reduction in myocardial NE content was found
at 8 weeks, suggesting cardiac sympathetic denervation,
impaired release or synthesis. In addition, similar to our
study and using a low-dose STZ non-insulin-dependent
DM mouse model, Kusmic et al. found increased urinary
NE excretion and reduced myocardial NE content at 7
weeks post DM induction [45]. Using imaging of 123I-
metaiodobenzylguanidine myocardial retention by single-
photon emission computed tomography to evaluate the
function of sympathetic neuronal endings, Kusmic et al.
found accelerated tracer washout, indicating reduced NE
uptake, and they suggested this might be due to decreased
NE transporter expression [45]. In the present study,
we also found a significant reduction in heart rate. Collect-
ively, our data support altered myocardial autonomic con-
trol/dysfunction. Future studies should measure myocardial
and urinary NE levels before and after 8 weeks as well as
other markers of cardiac autonomic dysfunction such as
heart rate variability.
Deficits in cardiac sensory afferents, another aspect of
DM cardiac pathology that may reflect neuropathy, have
been linked to changes in sensory neuronal markers
such as CGRP [46]. Using STZ mice, Ieda et al. found a
decrease in CGRP immunoreactivity and CGRP-specific
denervation in DM hearts at 16 weeks but not at 8
weeks of DM [46]. In female Wistar rats, Chottova et al.
found increases in CGRP content in DM hearts at 4, 8,
and 16 weeks after STZ, as a result of accumulation at
the dystrophic terminals [47]. Together, these observations
may reflect early dysfunction at the nerve terminal, with
impaired release of neurotransmitters (elevated CGRP)
and later events associated with cardiac denervation
(decreased CGRP). In the present study, we observed
elevated myocardial CGRP protein levels at 8 weeks,
suggesting early terminal dysfunction with CGRP accumu-
lation and impaired release. On the other hand, cardiac
neuronal remodeling affecting sympathetic and parasym-
pathetic control of cardiac function have been studied
using staining for acetylcholinesterase [48], molecular
imaging [49] and pan-neuronal markers such as PGP9.5
[50]. In cardiac tissue, PGP9.5 is expressed by parasympa-
thetic, sympathetic and sensory nerves and intracardiac
neurons. Our results showed no difference in PGP9.5 im-
munoreactivity in whole cardiac tissue suggesting that
at least PGP9.5 positive neurons are not widely affected.
Future studies should test for local staining of these
markers to better evaluate regional remodeling of neur-
onal subpopulations.
Limitations
We have qualified our STZ model, as non-insulin de-
pendent, but would not refer to as a type 2 model, since
Marangoni et al. Cardiovascular Diabetology 2014, 13:11 Page 9 of 10
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Therefore, our results cannot be applied to other types of
diabetes. We measured behavioral responses to noxious
thermal and non-noxious tactile stimuli and did not evalu-
ate for chemogenic pain or vibration changes. As noted
above these latter measurements should be incorporated
into future studies. Finally, for our cardiac neuronal stud-
ies our sample size was small, therefore these results are
qualified as ‘preliminary’ and interpreted with caution.
Conclusions
In summary, in a non-insulin-dependent STZ-DM ro-
dent model and as early as 4 weeks after the onset of
DM, we found evidence of the co-occurrence of ven-
tricular remodeling, systolic dysfunction, and DSPN. Re-
duced myocardial NE content, reduced heart rate, and
altered myocardial levels of biomarkers of sensory in-
nervation may indicate the presence of cardiovascular
autonomic neuropathy. Understanding the onset and
temporal relationship of common complications in ani-
mal models frequently used in pre-clinical studies, may
lead to a better understanding of the pathophysiology
underlying these complications. These studies also sug-
gest the need to screen for cardiovascular dysfunction in
DM patients presenting with insensate neuropathy.
Additional file
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(SO3), Red trace: water blank.
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